Published in PLoS One on December 19, 2013
Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2. Science (2015) 1.97
HOTAIR: an oncogenic long non-coding RNA in different cancers. Cancer Biol Med (2015) 1.40
Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood (2014) 1.23
Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2. Nat Commun (2016) 1.06
Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance. Nat Commun (2016) 0.95
Targeting EZH2 and PRC2 dependence as novel anticancer therapy. Exp Hematol (2015) 0.95
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Clin Epigenetics (2016) 0.95
Maintaining cell identity: PRC2-mediated regulation of transcription and cancer. Nat Rev Cancer (2016) 0.93
Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors. Oncotarget (2015) 0.92
Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes. Oncotarget (2015) 0.85
Evolving Catalytic Properties of the MLL Family SET Domain. Structure (2015) 0.83
Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood (2016) 0.82
Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention. Curr Opin Oncol (2015) 0.79
Long Noncoding RNAs as Novel Biomarkers Have a Promising Future in Cancer Diagnostics. Dis Markers (2016) 0.78
Apollo-NADP(+): a spectrally tunable family of genetically encoded sensors for NADP(.). Nat Methods (2016) 0.78
Structural insights into binding of small molecule inhibitors to Enhancer of Zeste Homolog 2. J Comput Aided Mol Des (2014) 0.77
The Human Mixed Lineage Leukemia 5 (MLL5), a Sequentially and Structurally Divergent SET Domain-Containing Protein with No Intrinsic Catalytic Activity. PLoS One (2016) 0.75
Structural analysis of an active fungal PRC2. Nucleus (2016) 0.75
Histone deacetylase inhibition modulates histone acetylation at gene promoter regions and affects genome-wide gene transcription in Schistosoma mansoni. PLoS Negl Trop Dis (2017) 0.75
Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors. J Med Chem (2016) 0.75
Molecular architecture of polycomb repressive complexes. Biochem Soc Trans (2017) 0.75
Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED. PLoS One (2017) 0.75
Histone lysine methyltransferases as anti-cancer targets for drug discovery. Acta Pharmacol Sin (2016) 0.75
MUC1-C activates EZH2 expression and function in human cancer cells. Sci Rep (2017) 0.75
Role of the long non-coding RNA HOTAIR in hepatocellular carcinoma. Oncol Lett (2017) 0.75
Polycomb repressive complex 2 in an autoinhibited state. J Biol Chem (2017) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science (2002) 24.31
Dali server: conservation mapping in 3D. Nucleic Acids Res (2010) 24.29
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature (2000) 18.26
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes. Acta Crystallogr D Biol Crystallogr (2006) 13.29
Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell (2002) 13.05
Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell (2002) 12.28
The Polycomb complex PRC2 and its mark in life. Nature (2011) 11.97
MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res (2004) 9.86
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature (2011) 9.71
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010) 7.96
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J (2004) 7.32
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell (2004) 6.90
Role of the polycomb protein EED in the propagation of repressive histone marks. Nature (2009) 6.62
Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res (2008) 6.46
Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev (2004) 6.19
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
Regulation of p53 activity through lysine methylation. Nature (2004) 5.78
Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. Mol Cell (2004) 5.06
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A (2010) 4.52
Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc Natl Acad Sci U S A (2006) 4.45
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood (2010) 4.02
Structure and catalytic mechanism of the human histone methyltransferase SET7/9. Nature (2003) 4.00
The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol (2005) 3.93
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol (2012) 3.89
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci U S A (2012) 3.22
Aberrations of EZH2 in cancer. Clin Cancer Res (2011) 3.13
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A (2012) 3.03
Structural and functional analysis of SET8, a histone H4 Lys-20 methyltransferase. Genes Dev (2005) 2.56
Specificity and mechanism of the histone methyltransferase Pr-Set7. Genes Dev (2005) 2.50
Structural biology of human H3K9 methyltransferases. PLoS One (2010) 2.45
Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks. Mol Cell (2009) 2.32
Crystal structure and functional analysis of the histone methyltransferase SET7/9. Cell (2002) 2.27
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A (2013) 2.26
An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol (2013) 1.89
Mechanism of histone lysine methyl transfer revealed by the structure of SET7/9-AdoMet. EMBO J (2003) 1.89
Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol (2013) 1.75
Structural origins for the product specificity of SET domain protein methyltransferases. Proc Natl Acad Sci U S A (2008) 1.72
Molecular architecture of human polycomb repressive complex 2. Elife (2012) 1.64
Dominant alleles identify SET domain residues required for histone methyltransferase of Polycomb repressive complex 2. J Biol Chem (2008) 1.58
Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci (2011) 1.57
Polycomb group suppressor of zeste 12 links heterochromatin protein 1alpha and enhancer of zeste 2. J Biol Chem (2003) 1.45
The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Lett (2011) 1.42
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer (2010) 1.42
The structure of NSD1 reveals an autoregulatory mechanism underlying histone H3K36 methylation. J Biol Chem (2010) 1.41
Structural chemistry of the histone methyltransferases cofactor binding site. J Chem Inf Model (2011) 1.23
EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development. Mod Pathol (2011) 1.21
Structural Chemistry of Human SET Domain Protein Methyltransferases. Curr Chem Genomics (2011) 1.20
Sinefungin derivatives as inhibitors and structure probes of protein lysine methyltransferase SETD2. J Am Chem Soc (2012) 1.17
Structure of human SMYD2 protein reveals the basis of p53 tumor suppressor methylation. J Biol Chem (2011) 1.01
Molecular basis for the regulation of the H3K4 methyltransferase activity of PRDM9. Cell Rep (2013) 0.98
Structural basis of SETD6-mediated regulation of the NF-kB network via methyl-lysine signaling. Nucleic Acids Res (2011) 0.97
EZH2 mutations are related to low blast percentage in bone marrow and -7/del(7q) in de novo acute myeloid leukemia. PLoS One (2013) 0.92
Molecular pathways: protein methyltransferases in cancer. Clin Cancer Res (2013) 0.90
Convergent evolution of chromatin modification by structurally distinct enzymes: comparative enzymology of histone H3 Lys²⁷ methylation by human polycomb repressive complex 2 and vSET. Biochem J (2013) 0.78
Structural biology of human H3K9 methyltransferases. PLoS One (2010) 2.45
Structural and histone binding ability characterizations of human PWWP domains. PLoS One (2011) 1.32
Assessment of a method to characterize antibody selectivity and specificity for use in immunoprecipitation. Nat Methods (2015) 1.00
Thermal denaturation assays in chemical biology. Assay Drug Dev Technol (2011) 0.97
A cellular chemical probe targeting the chromodomains of Polycomb repressive complex 1. Nat Chem Biol (2016) 0.97
Structural basis of allele variation of human thiopurine-S-methyltransferase. Proteins (2007) 0.97
Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target. Oncotarget (2016) 0.94
RPRD1A and RPRD1B are human RNA polymerase II C-terminal domain scaffolds for Ser5 dephosphorylation. Nat Struct Mol Biol (2014) 0.90
The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex. Nat Chem Biol (2017) 0.89
A Basic Post-SET Extension of NSDs Is Essential for Nucleosome Binding In Vitro. J Biomol Screen (2014) 0.80
A Radioactivity-Based Assay for Screening Human m6A-RNA Methyltransferase, METTL3-METTL14 Complex, and Demethylase ALKBH5. J Biomol Screen (2015) 0.78
WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma. Cancer Res (2015) 0.76
The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity. Nat Chem Biol (2017) 0.75